Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more

Deferred cytoreductive nephrectomy in kidney cancer fails to improve progression-free survival

Results from the phase 3 CARMENA study, published in the journal JAMA Oncology, found that pretreatment of renal cell carcinoma (RCC) patients with sunitinib followed by deferred cytoreductive nephrectomy did not improve 28-week progression-free survival rates compared with immediate nephrectomy followed by sunitinib in these patients. However, patients who received sunitinib followed by deferred cytoreductive […]

read more

Advances and next steps in kidney cancer

In an interview with OncLive, Dr Toni Choueiri from Harvard Medical School, Dana-Farber Cancer Institute in America, discusses recent progress in renal cell carcinoma (RCC) and future research in this area. Dr Choueiri talks about the breakthroughs in the treatment of patients with RCC over the last decade, such as checkpoint inhibitors, targeted agents, and combination […]

read more

Prognostic markers for kidney cancer

A recent study published in the Lancet Oncology has identified that the mutation status of three genes – BAP1, PBRM1, and TP53 – had independent prognostic value for patients with advanced or metastatic renal cell carcinoma (RCC) about to start treatment with first-line tyrosine kinase inhibitors (TKIs). The mutation status of these three genes is useful for helping to determine […]

read more

Exercise significantly cuts the risk of death from cancer

New research from an American group based at Roswell Park Comprehensive Cancer Center, New York shows that if cancer patients exercise regularly both before and after their diagnosis, they are significantly more likely to survive cancer than those who are sedentary. This adds to the growing evidence that physical activity is important for the prevention […]

read more

Cancer drugs taking longer to reach NHS patients

A new report by the Institute of Cancer Research (ICR) has found that patients are waiting longer for new cancer drugs to be approved for use with the NHS because of delays in clinical trials and regulatory approval for use. The report found that the average time taken from the start of phase I clinical […]

read more

First NHS cancer patient to begin treatment with proton beam therapy in Manchester

Cally Palmer, NHS England’s national cancer director announced at the Britain Against Cancer conference yesterday that the first patient in England is to begin state of the art proton beam therapy for cancer at The Christie Hospital in Manchester this month, marking a major milestone for NHS care. The second proton beam therapy machine is […]

read more

Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

This multicentre analysis of axitinib versus sunitinib used as first-line treatment for metastatic renal cell carcinoma (RCC) in 169 patients shows that compared with sunitinib, axitinib significantly prolonged cancer-specific survival and overall survival. Axitinib also had a safer adverse event profile compared to sunitinib as a first-line therapy for previously untreated metastatic RCC. Read the […]

read more

Robot-assisted surgery available in East Lancashire

Three talented surgeons have performed what is believed to be the first combined renal and bowel cancer surgery in the North West using robotic surgery assisted by the Da Vinci robot. The surgery was performed at the Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust. The patient was given pioneering surgery involving a partial […]

read more

Nivolumab-ipilimumab combination delays the need for additional treatment in kidney cancer patients

A recent analysis of data from the phase 3 Checkmate-214 clinical trial showed that first-line treatment with the nivolumab/ipilimumab combination significantly delayed the need for subsequent treatment in patients with advanced or metastatic renal cell carcinoma (RCC), compared with standard treatment with sunitinib. This benefit was also seen in patients who had stopped treatment, and […]

read more
Showing 11 to 20 of 432 results
  TOP